Easter Fundraising
If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!
Search results
If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
The latest research news from Retina UK.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
Ocugen have recently announced that they have completed enrolment and dosing in their pivotal phase 2/3 trial of OCU410ST ahead of schedule.
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Promising early clinical trial results suggest that ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), could offer a potential new treatment approach for this rate inherited retinal condition.
Caryn talks about her experience taking part in the 2021 Virtual London Marathon.
Retina UK has joined with more than 80 disability charities who have today written to the Chancellor calling for urgent support with the cost of living for disabled people.
Join us for a practical webinar exploring simple steps you can take to protect your remaining vision, maintain good eye health, and make the most of the sight you have.